# Cardio-Oncology Midwest Regional Symposium

> **NIH NIH R13** · RUSH UNIVERSITY MEDICAL CENTER · 2021 · $10,000

## Abstract

Paradigms in Cardiovascular Care of the Cancer Patient/Survivor – Biennial Cardio-
Oncology Midwest Regional Educational Symposium
Abstract
Second to cardiovascular disease (CVD) in the U.S., cancer remains the leading cause of death
in the world. Nonetheless, the overall death rate from cancer has declined, and the number of
cancer survivors has increased as a result of advancements in oncologic treatment, and greater
attention by providers to prevention and surveillance for adverse outcomes. By January 1, 2030,
it is estimated that the population of cancer survivors will increase to more than 22.1 million due
to the growth and aging of the population alone.
CVD is the major cause of morbidity and mortality among cancer survivors, and is considered to
be a major cause of mortality among cancer survivors aged 15 to 39 years old. Many
therapeutic approaches to cancer significantly increase the risk of cardiomyopathy, ischemia,
cardiovascular events (including myocardial infarction and ventricular arrhythmias), and
hypertension.
Cardio-oncology is a nascent field that focuses on preventing adverse cardiovascular outcomes
in patients with active cancer and improving the overall cardiovascular health of cancer
survivors. This involves specific understanding of interactions between cancer and the
cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including
chemotherapy, radiation therapy, and newer targeted therapies/immunotherapy. The field of
cardio-oncology is becoming more specialized with constant variations in cancer treatment; and
emphasizes a great need to educate and keep clinician up to date. This is particularly important
for primary doctors and other caregivers that remain peripherally involved in routine care of
cancer patient; and need to be cognizant or aware of cancer therapy(ies) received, short and
long-term side effects, and management strategies.
We propose an educational activity that will provide the latest clinical updates in the treatment of
cardiovascular conditions in an oncology setting. The purpose of this program is to familiarize
primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers,
pharmacists, and trainees, with updated treatment of cardiac conditions seen in cancer patients/
survivors; as well as identify ongoing research to further improve our understanding of cancer
therapy-related cardiovascular dysfunction to further enhance management strategies for the
future. Given the paucity of cardio-oncology specialists in many parts of the U.S., the program
will arm general practitioners with practical tools to promote the prevention and treatment of
CVD as a result of cancer therapy, to help their cancer patients live longer and healthier lives.

## Key facts

- **NIH application ID:** 10391683
- **Project number:** 1R13CA268650-01
- **Recipient organization:** RUSH UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Tochukwu E.M Okwuosa
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $10,000
- **Award type:** 1
- **Project period:** 2021-09-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10391683

## Citation

> US National Institutes of Health, RePORTER application 10391683, Cardio-Oncology Midwest Regional Symposium (1R13CA268650-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10391683. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*